BC Week In Review | Oct 5, 2018
Company News

Janssen terminates licenses to Aduro cancer therapies

Aduro BioTech Inc. (NASDAQ:ADRO) revealed in an SEC filing that the Janssen Biotech Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) will terminate its licenses for three cancer therapies, effective Dec. 24. A Janssen spokesperson told...
BC Week In Review | Dec 1, 2016
Clinical News

CRS-207: Ph IIb resumed

Aduro said FDA lifted a partial clinical hold on trials evaluating candidates developed using the company's L. monocytogenes -based immunotherapy construct (LADD) platform. The studies may resume enrollment. Patients in the trials continued to receive...
BC Extra | Nov 21, 2016
Clinical News

FDA lifts partial hold on Aduro's candidates

Aduro Biotech Inc. (NASDAQ:ADRO) said FDA lifted a partial clinical hold on trials evaluating candidates developed using the company's Listeria monocytogenes -based immunotherapy construct (LADD) platform. The studies may resume enrollment. Patients in the trials...
BC Week In Review | Oct 31, 2016
Clinical News

CRS-207: Phase IIb hold

Aduro said FDA placed a partial clinical hold on trials evaluating candidates developed through the company’s live-attenuated double-deleted Listeria monocytogenes (LADD) technology. The hold pauses new patient enrollment but allows patients already treated with LADD-based...
BC Extra | Oct 24, 2016
Clinical News

Partial clinical hold for Aduro's Listeria candidates

Aduro Biotech Inc. (NASDAQ:ADRO) slipped $0.55 to $11.70 on Monday after it said FDA placed a partial clinical hold on trials evaluating candidates developed using the company's Listeria monocytogenes -based immunotherapy construct (LADD) platform. The...
BC Week In Review | Jan 18, 2016
Clinical News

ADU-214: Phase I started

Johnson & Johnson’s Janssen Biotech Inc. unit began a 2-part, open-label, U.S. Phase I trial to evaluate IV ADU-214 once every 21 days in 42 patients with advanced or metastatic NSCLC. The dose-escalation part 1...
Items per page:
1 - 6 of 6